Marco Peter Leu
CSO
abc biopply
Solothurn, Switzerland
6 profile visits
At abc biopply, we are advancing drug discovery and development through robust, validated, and highly reliable disease models.
My organisation
abc biopply is a Swiss preclinical CRO pioneering humanized multi-organoid disease models to accelerate drug discovery while reducing reliance on animal testing. Using our proprietary 3D CoSeedis™ multi-organoid in-chip technology, we provide scalable, highly standardized organoid assays that enable physiologically relevant drug efficacy, resistance, and safety studies. Our platform bridges the preclinical complexity gap by combining tissue-level biological relevance with statistically robust experimental throughput, enabling predictive insights earlier in the discovery pipeline. We collaborate with biotech, pharma, and CRO partners seeking advanced New Approach Methodologies (NAMs), human-relevant disease models, and integrated preclinical studies supporting candidate selection, translational validation, and mechanism-of-action research.
About me
Trained as a neurobiologist, I have spent the past 25 years working in international companies focused on drug discovery and development. Throughout my career, I have specialized in cell-based assays for hHTS/HCS applications. I currently apply and share this expertise through abc biopply’s preclinical disease modelling initiatives.